NCT07224321RecruitingPhase 2
INHALE-1st: Technosphere Insulin (Afrezza®) In Combination With Basal Insulin For Youth With Newly-Diagnosed Type 1 Diabetes
Mannkind Corporation10 sites in 1 country100 target enrollmentStarted: February 4, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Mannkind Corporation
- Enrollment
- 100
- Locations
- 10
- Primary Endpoint
- Percentage of participants with Continuous Glucose Meter (CGM) measured time in range (TIR) ≥70%
Study Overview
Brief Summary
INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 6 to <18 years old with newly diagnosed stage 3 type 1 diabetes (T1D). The study will also evaluate the effect of an Afrezza plus BI reigmen on participant and parent/legally authorized representative satisfaction. Participants will be followed for 13 weeks during the main phase followed by an optional Extension Phase for participants continuing to use Afrezza in combination with BI for up to 26 weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 6 Years to 17 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 6 to <18 years of age
- •Clinical diagnosis of stage 3 T1D, per the investigator. Stage 3 is defined as hyperglycemia, meeting ADA glycemic and clinical diagnostic criteria
- •Able to start the Afrezza-BI regimen within 21 days following T1D diagnosis (day 1 is based on the first insulin dose)
- •Forced Expiratory Volume in One Second (FEV1) >80.0% of predicted Global Lung Function Initiative (GLI) value
- •Investigator believes that participant can be expected to follow the study protocol
- •No medical, psychiatric, psychosocial conditions, or medications being taken that in the investigator's judgment would be a safety concern for participation in the study
Exclusion Criteria
- •Prior insulin treatment for stage 2 T1D
- •In the judgment of the investigator, history of chronic lung disease, such as asthma, or chronic obstructive pulmonary disease, lung cancer, or any other clinically important pulmonary disease (e.g., cystic fibrosis, bronchopulmonary dysplasia)
- •Allergy or known hypersensitivity to human regular insulin
- •Smoking (includes cigarettes, cigars, pipes, marijuana, and vaping devices) within 3 months prior to screening and/or positive cotinine test for smoking
- •Positive urine pregnancy test for female subjects of childbearing potential
Arms & Interventions
Afrezza (Technosphere Insulin) + Basal Insulin
Experimental
Individualized dose of Afrezza (Technosphere Insulin) and basal insulin for each patient before each meal (breakfast, lunch, and dinner) for 13 weeks.
Intervention: Technosphere Insulin (Drug)
Afrezza (Technosphere Insulin) + Basal Insulin
Experimental
Individualized dose of Afrezza (Technosphere Insulin) and basal insulin for each patient before each meal (breakfast, lunch, and dinner) for 13 weeks.
Intervention: Basal insulin (Drug)
Outcomes
Primary Outcomes
Percentage of participants with Continuous Glucose Meter (CGM) measured time in range (TIR) ≥70%
Time Frame: 13 weeks
Percentage of participants with a CGM-measured TIR 70-180 mg/dL ≥70% during 14 days prior to 13-week visit
Secondary Outcomes
- Change in percent predicted FEV1(39 weeks)
- Incidence and severity of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)(39 weeks)
- Mean Continuous Glucose Monitoring (CGM) glucose(13 weeks)
- Continuous Glucose Monitoring (CGM) measured time-in-tight-range 70-140 mg/dL(13 weeks)
- Continuous Glucose Monitoring (CGM) measured percent time with glucose greater than 180 mg/dL(13 weeks)
- Continuous Glucose Monitoring (CGM) measured time with glucose greater than 250 mg/dL(13 weeks)
- Continuous Glucose Monitoring (CGM) measured time with glucose less than 70 mg/dL(13 weeks)
- Continuous Glucose Monitoring (CGM) measured time with glucose less than 54 mg/dL(13 weeks)
- Continuous Glucose Monitoring (CGM) measured coefficient of variation(13 weeks)
- Change in glycated hemoglobin (HbA1c)(13 weeks)
- Percentage of participants using Afrezza and basal insulin (Afrezza-BI) regimen(At 13 weeks)
- Percentage of participants that continue on the Afrezza and basal insulin (Afrezza-BI) regimen(After 13 weeks)
- Incidence of Adverse Events of Special Interest (AESIs)(39 weeks)
- Patient Reported Outcome: Insulin Treatment Satisfaction Questionnaire (ITSQ), Caregiver(13 weeks)
- Patient Reported Outcome: Insulin Treatment Satisfaction Questionnaire (ITSQ), Participant(13 weeks)
- Patient Reported Outcome: Insulin Treatment Satisfaction Questionnaire (ITSQ), Caregiver(39 weeks)
- Patient Reported Outcome: Insulin Treatment Satisfaction Questionnaire (ITSQ), Participant(39 weeks)
- Incidence of Adverse Events of Special Interest (AESIs)(13 weeks)
- Change in percent predicted FEV1(13 weeks)
- Incidence and severity of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)(13 weeks)
Investigators
Study Sites (10)
Loading locations...
Similar Trials
Completed
Phase 1
FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney TransplantationIschemia-reperfusion InjuryKidney Transplant ComplicationsNCT05246618iCoat Medical AB18
Terminated
Phase 1
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01Alzheimer DiseaseNCT06247345Alzheimer's Disease Expert Lab (ADEL), Inc.42
Completed
Phase 1
Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy SubjectsPhase 1NCT05068947Graviton Bioscience Corporation16
Terminated
Phase 1
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsMyeloproliferative NeoplasmMyelodysplastic/Myeloproliferative NeoplasmAcute Myeloid LeukemiaNCT04637009Astex Pharmaceuticals, Inc.20
Active, not recruiting
Phase 1
Phase 1 Study of OLX-07010 in Healthy Adult and Elderly ParticipantsAlzheimer DiseaseNCT05696483Oligomerix, Inc76